11:@0.895357:0.033217:0.916054:0.033217:0.916054:0.013052:0.895357:0.013052:0.010348:0.010348
HANDBOOK OF GENERAL MEDICINE VOL 1:@0.649278:0.972666:0.923020:0.972666:0.923020:0.958637:0.649278:0.958637:0.009179:0.009945:0.009945:0.009999:0.007714:0.011679:0.011679:0.007943:0.003723:0.011679:0.006518:0.003723:0.011719:0.007203:0.009945:0.007203:0.008158:0.009945:0.006209:0.003723:0.012351:0.007203:0.009999:0.003037:0.010926:0.003037:0.009945:0.007203:0.003723:0.009434:0.011679:0.006209:0.003723:0.007445
TREATMENT AppROACHEs:@0.983817:0.243404:0.983817:0.056390:0.958557:0.056390:0.958557:0.243404:0.008796:-0.015759:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.114251:0.006043:0.014598:-0.134892:0.158618:-0.158618:0.000000:0.000000:0.000000:0.000000:0.242660:0.009202
TREATMENT AppROACHEs:@0.397039:0.033156:0.624383:0.033156:0.624383:0.013866:0.397039:0.013866:0.007872:0.011217:0.009905:0.013674:0.007872:0.016982:0.009905:0.013674:0.007872:0.005119:0.013674:0.010939:0.010939:0.011217:0.016058:0.013674:0.015023:0.012621:0.009905:0.009202
Patients with multiple comorbidities and diabetes: :@0.076190:0.099847:0.891274:0.099847:0.891274:0.063183:0.076190:0.063183:0.018815:0.022175:0.010079:0.008063:0.021503:0.020159:0.010079:0.014783:0.009407:0.026878:0.008063:0.010079:0.020159:0.009407:0.031582:0.020159:0.008063:0.010079:0.008063:0.022175:0.008063:0.021503:0.009407:0.021503:0.021503:0.031582:0.021503:0.010751:0.022175:0.008063:0.022175:0.008063:0.010079:0.008063:0.021503:0.014783:0.009407:0.022175:0.020159:0.022175:0.009407:0.022175:0.008063:0.022175:0.022175:0.021503:0.010079:0.021503:0.014783:0.009407:0.009407
management challenges:@0.076190:0.128069:0.488772:0.128069:0.488772:0.091406:0.076190:0.091406:0.031582:0.022175:0.020159:0.022175:0.022175:0.021503:0.031582:0.021503:0.020159:0.010079:0.009407:0.021503:0.020159:0.022175:0.008063:0.008063:0.021503:0.020159:0.022175:0.021503:0.014783
A Kok:@0.076190:0.169924:0.124235:0.169924:0.124235:0.151592:0.076190:0.151592:0.012431:0.004704:0.010415:0.010751:0.009743
MBChB Dippec FCp (sA) MMed FACp BTheol FRCp (London):@0.076190:0.182033:0.464810:0.182033:0.464810:0.168004:0.076190:0.168004:0.012351:0.007714:0.010926:0.008198:0.007714:0.003723:0.009999:0.002688:0.009165:0.007956:0.008735:0.008695:0.003723:0.006518:0.010926:0.007956:0.003723:0.004959:0.006693:0.009945:0.004959:0.003723:0.012351:0.012351:0.008735:0.009206:0.003723:0.006518:0.009945:0.010926:0.007956:0.003723:0.007714:0.005725:0.008198:0.008735:0.008803:0.002688:0.003723:0.006518:0.008158:0.010926:0.007956:0.003723:0.004959:0.006209:0.008803:0.008198:0.009206:0.008803:0.008198:0.004959
Specialist Physician in Private Practice, Johannesburg:@0.076190:0.200064:0.422316:0.200064:0.422316:0.186035:0.076190:0.186035:0.006693:0.009165:0.008735:0.008695:0.002688:0.009179:0.002688:0.002688:0.005214:0.004556:0.003723:0.007956:0.008198:0.007203:0.005214:0.002688:0.008695:0.002688:0.009179:0.008198:0.003723:0.002688:0.008198:0.003723:0.007956:0.004045:0.002688:0.007445:0.009179:0.004556:0.008735:0.003723:0.007956:0.004045:0.009179:0.008695:0.004556:0.002688:0.008695:0.008735:0.003723:0.003723:0.006478:0.008803:0.008198:0.009179:0.008198:0.008198:0.008735:0.005214:0.009165:0.008171:0.004045:0.009045
It has become clear in recent months that HIV/AIDs has :@0.076190:0.230029:0.485130:0.230029:0.485130:0.214246:0.076190:0.214246:0.003417:0.005125:0.003976:0.009223:0.010326:0.005866:0.003976:0.010311:0.009827:0.009782:0.009903:0.014182:0.009827:0.003976:0.009782:0.003024:0.009827:0.010326:0.004551:0.003976:0.003024:0.009223:0.003976:0.004551:0.009827:0.009782:0.009827:0.009223:0.005110:0.003976:0.014182:0.009903:0.009223:0.005125:0.009223:0.005866:0.003976:0.005125:0.009223:0.010326:0.005125:0.003976:0.010326:0.003417:0.010614:0.006607:0.011188:0.003417:0.011249:0.007529:0.003991:0.009223:0.010326:0.005866:0.004188
moved to fifth place as a cause of mortality in South Af:@0.076190:0.244206:0.475938:0.244206:0.475938:0.228424:0.076190:0.228424:0.014182:0.009903:0.008376:0.009827:0.010357:0.003976:0.005125:0.009903:0.003961:0.003681:0.003681:0.004747:0.005125:0.009223:0.003961:0.010311:0.003024:0.010326:0.009782:0.009827:0.003976:0.010326:0.005866:0.003976:0.010326:0.003976:0.009782:0.010326:0.009192:0.005866:0.009827:0.003976:0.009903:0.004747:0.003961:0.014182:0.009903:0.004551:0.005125:0.010326:0.003024:0.003024:0.005125:0.008104:0.003961:0.003024:0.009223:0.003976:0.007529:0.009903:0.009192:0.005125:0.009223:0.003961:0.011188:0.004747
-:@0.475938:0.244206:0.480957:0.244206:0.480957:0.228424:0.475938:0.228424:0.005020
rica. It has been replaced by cardiovascular disease as :@0.076190:0.258384:0.485145:0.258384:0.485145:0.242602:0.076190:0.242602:0.004551:0.003024:0.009782:0.010326:0.004188:0.004082:0.003417:0.005125:0.004082:0.009223:0.010326:0.005866:0.004082:0.010311:0.009827:0.009827:0.009223:0.004082:0.004551:0.009827:0.010311:0.003024:0.010326:0.009782:0.009827:0.010357:0.004082:0.010311:0.008104:0.004082:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.004082:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.004082:0.010326:0.005866:0.004188
number one, while diabetes is number two. south Africa :@0.076190:0.272562:0.485145:0.272562:0.485145:0.256779:0.076190:0.256779:0.009223:0.009192:0.014182:0.010311:0.009827:0.004551:0.003674:0.009903:0.009223:0.009827:0.004188:0.003674:0.012564:0.009223:0.003024:0.003024:0.009827:0.003689:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.003689:0.003024:0.005866:0.003689:0.009223:0.009192:0.014182:0.010311:0.009827:0.004551:0.003674:0.005125:0.012564:0.009903:0.004188:0.003704:0.007529:0.009903:0.009192:0.005125:0.009223:0.003674:0.011188:0.004747:0.004551:0.003024:0.009782:0.010326:0.004188
is facing an epidemic of lifestyle diseases and the need :@0.076190:0.286740:0.485115:0.286740:0.485115:0.270957:0.076190:0.270957:0.003024:0.005866:0.004143:0.004747:0.010326:0.009782:0.003024:0.009223:0.010175:0.004127:0.010326:0.009223:0.004127:0.009827:0.010311:0.003024:0.010357:0.009827:0.014182:0.003024:0.009782:0.004143:0.009903:0.004747:0.004127:0.003024:0.003024:0.004747:0.009827:0.005866:0.005125:0.008104:0.003024:0.009827:0.004127:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.005866:0.004143:0.010326:0.009223:0.010357:0.004127:0.005125:0.009223:0.009827:0.004127:0.009223:0.009827:0.009827:0.010357:0.004188
to educate patients and their families accordingly be-:@0.076190:0.300918:0.480942:0.300918:0.480942:0.285135:0.076190:0.285135:0.005125:0.009903:0.005337:0.009827:0.010357:0.009192:0.009782:0.010326:0.005125:0.009827:0.005337:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.005337:0.010326:0.009223:0.010357:0.005337:0.005125:0.009223:0.009827:0.003024:0.004551:0.005337:0.004747:0.010326:0.014182:0.003024:0.003024:0.003024:0.009827:0.005866:0.005352:0.010326:0.009782:0.009782:0.009903:0.004551:0.010357:0.003024:0.009223:0.010175:0.003024:0.008104:0.005337:0.010311:0.009827:0.005020
comes paramount as this challenge is not always met :@0.076190:0.315096:0.485130:0.315096:0.485130:0.299313:0.076190:0.299313:0.009782:0.009903:0.014182:0.009827:0.005866:0.005715:0.010311:0.010326:0.004551:0.010326:0.014182:0.009903:0.009192:0.009223:0.005125:0.005700:0.010326:0.005866:0.005715:0.005125:0.009223:0.003024:0.005866:0.005715:0.009782:0.009223:0.010326:0.003024:0.003024:0.009827:0.009223:0.010175:0.009827:0.005715:0.003024:0.005866:0.005715:0.009223:0.009903:0.005125:0.005700:0.010326:0.003024:0.012564:0.010326:0.008104:0.005866:0.005730:0.014182:0.009827:0.005125:0.004188
by medicines administration, but rather by the lifestyle :@0.076190:0.329273:0.485130:0.329273:0.485130:0.313491:0.076190:0.313491:0.010311:0.008104:0.005775:0.014182:0.009827:0.010357:0.003024:0.009782:0.003024:0.009223:0.009827:0.005866:0.005775:0.010326:0.010357:0.014182:0.003024:0.009223:0.003024:0.005866:0.005125:0.004551:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188:0.005760:0.010311:0.009192:0.005125:0.005760:0.004551:0.010326:0.005125:0.009223:0.009827:0.004551:0.005760:0.010311:0.008104:0.005775:0.005125:0.009223:0.009827:0.005760:0.003024:0.003024:0.004747:0.009827:0.005866:0.005125:0.008104:0.003024:0.009827:0.004188
choices people make. :@0.076190:0.343451:0.245478:0.343451:0.245478:0.327669:0.076190:0.327669:0.009782:0.009223:0.009903:0.003024:0.009782:0.009827:0.005866:0.004188:0.010311:0.009827:0.009903:0.010311:0.003024:0.009827:0.004188:0.014182:0.010326:0.007590:0.009827:0.004188:0.004188
The population is increasingly faced with comorbidi-:@0.090478:0.357629:0.480957:0.357629:0.480957:0.341846:0.090478:0.341846:0.006441:0.009223:0.009827:0.005760:0.010311:0.009903:0.010311:0.009192:0.003024:0.010326:0.005125:0.003024:0.009903:0.009223:0.005760:0.003024:0.005866:0.005775:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.003024:0.009223:0.010175:0.003024:0.008104:0.005760:0.004747:0.010326:0.009782:0.009827:0.010357:0.005760:0.012564:0.003024:0.005125:0.009223:0.005760:0.009782:0.009903:0.014182:0.009903:0.004551:0.010311:0.003024:0.010357:0.003024:0.005020
ties in a single individual. There are no precise statistics :@0.076190:0.371807:0.485145:0.371807:0.485145:0.356024:0.076190:0.356024:0.005125:0.003024:0.009827:0.005866:0.005231:0.003024:0.009223:0.005231:0.010326:0.005231:0.005866:0.003024:0.009223:0.010175:0.003024:0.009827:0.005231:0.003024:0.009223:0.010357:0.003024:0.008376:0.003024:0.010357:0.009192:0.010326:0.003024:0.004188:0.005246:0.006441:0.009223:0.009827:0.004536:0.009827:0.005231:0.010326:0.004551:0.009827:0.005231:0.009223:0.009903:0.005231:0.010311:0.004551:0.009827:0.009782:0.003024:0.005866:0.009827:0.005231:0.005866:0.005125:0.010326:0.005125:0.003024:0.005866:0.005125:0.003024:0.009782:0.005866:0.004188
on  the  true  prevalence  of  all these  conditions  in the :@0.076190:0.385985:0.485130:0.385985:0.485130:0.370202:0.076190:0.370202:0.009903:0.009223:0.004188:0.003024:0.005125:0.009223:0.009827:0.004188:0.003024:0.005125:0.004551:0.009192:0.009827:0.004188:0.003024:0.010311:0.004551:0.009827:0.008376:0.010326:0.003024:0.009827:0.009223:0.009782:0.009827:0.004188:0.003024:0.009903:0.004747:0.004188:0.003024:0.010326:0.003024:0.003024:0.007227:0.005125:0.009223:0.009827:0.005866:0.009827:0.004188:0.003024:0.009782:0.009903:0.009223:0.010357:0.003024:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188:0.003024:0.003024:0.009223:0.007227:0.005125:0.009223:0.009827:0.004188
south African population, except for the  sANHANEs :@0.076190:0.400162:0.485175:0.400162:0.485175:0.384380:0.076190:0.384380:0.007529:0.009903:0.009192:0.005125:0.009223:0.008784:0.011188:0.004747:0.004551:0.003024:0.009782:0.010326:0.009223:0.008784:0.010311:0.009903:0.010311:0.009192:0.003024:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188:0.008784:0.009827:0.007257:0.009782:0.009827:0.010311:0.005125:0.008784:0.004747:0.009903:0.004551:0.008784:0.005125:0.009223:0.009827:0.004188:0.004596:0.007529:0.011188:0.011188:0.010326:0.011188:0.011188:0.008104:0.007529:0.004188
data from 2012.  In the IDF report  of 2015,  it became :@0.076190:0.414340:0.485130:0.414340:0.485130:0.398558:0.076190:0.398558:0.010357:0.010326:0.005125:0.010326:0.006970:0.004747:0.004551:0.009903:0.014182:0.006970:0.008376:0.008376:0.008376:0.008376:0.004188:0.004188:0.002797:0.003417:0.009223:0.006970:0.005125:0.009223:0.009827:0.006970:0.003417:0.011249:0.007333:0.006970:0.004551:0.009827:0.010311:0.009903:0.004551:0.005125:0.004188:0.002767:0.009903:0.004747:0.006970:0.008376:0.008376:0.008376:0.008376:0.004188:0.004188:0.002797:0.003024:0.005125:0.006970:0.010311:0.009827:0.009782:0.010326:0.014182:0.009827:0.004188
clear that non-communicable diseases, with diabetes :@0.076190:0.428518:0.485145:0.428518:0.485145:0.412735:0.076190:0.412735:0.009782:0.003024:0.009827:0.010326:0.004551:0.006320:0.005125:0.009223:0.010326:0.005125:0.006320:0.009223:0.009903:0.009207:0.005020:0.009782:0.009903:0.014182:0.014182:0.009192:0.009223:0.003024:0.009782:0.010326:0.010311:0.003024:0.009827:0.006320:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.005866:0.004188:0.006320:0.012564:0.003024:0.005125:0.009223:0.006320:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.004188
the  most important,  represent  a worldwide problem. :@0.076190:0.442696:0.485160:0.442696:0.485160:0.426913:0.076190:0.426913:0.005125:0.009223:0.009827:0.004188:0.003750:0.014182:0.009903:0.005866:0.005125:0.007953:0.003024:0.014182:0.010311:0.009903:0.004551:0.005125:0.010326:0.009223:0.005125:0.004188:0.004188:0.003750:0.004551:0.009827:0.010311:0.004551:0.009827:0.005866:0.009827:0.009223:0.005125:0.004188:0.003750:0.010326:0.007953:0.012564:0.009903:0.004551:0.003024:0.010357:0.012564:0.003024:0.010357:0.009827:0.007953:0.010311:0.004551:0.009903:0.010311:0.003024:0.009827:0.014182:0.004188:0.004188
Africa – especially sub-saharan Africa – represents the :@0.076190:0.456874:0.485130:0.456874:0.485130:0.441091:0.076190:0.441091:0.011188:0.004747:0.004551:0.003024:0.009782:0.010326:0.005458:0.007560:0.005458:0.009827:0.005866:0.010311:0.009827:0.009782:0.003024:0.010326:0.003024:0.003024:0.008104:0.005473:0.005866:0.009192:0.010311:0.005020:0.007529:0.010326:0.009223:0.010326:0.004551:0.010326:0.009223:0.005473:0.011188:0.004747:0.004551:0.003024:0.009782:0.010326:0.005458:0.007560:0.005458:0.004551:0.009827:0.010311:0.004551:0.009827:0.005866:0.009827:0.009223:0.005125:0.005866:0.005458:0.005125:0.009223:0.009827:0.004188
biggest challenge as so many patients are undiag-:@0.076190:0.471051:0.480942:0.471051:0.480942:0.455269:0.076190:0.455269:0.010311:0.003024:0.010175:0.010175:0.009827:0.005866:0.005125:0.008739:0.009782:0.009223:0.010326:0.003024:0.003024:0.009827:0.009223:0.010175:0.009827:0.008739:0.010326:0.005866:0.008739:0.005866:0.009903:0.008739:0.014182:0.010326:0.009223:0.008104:0.008739:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.008739:0.010326:0.004551:0.009827:0.008739:0.009192:0.009223:0.010357:0.003024:0.010326:0.010175:0.005020
nosed or diagnosed late with resultant complications.  :@0.076190:0.485229:0.485140:0.485265:0.485140:0.469482:0.076190:0.469447:0.009223:0.009903:0.005866:0.009827:0.010357:0.004294:0.009903:0.004551:0.004294:0.010357:0.003024:0.010326:0.010175:0.009223:0.009903:0.005866:0.009827:0.010357:0.004294:0.003024:0.010326:0.005125:0.009827:0.004294:0.012564:0.003024:0.005125:0.009223:0.004294:0.004551:0.009827:0.005866:0.009192:0.003024:0.005125:0.010326:0.009223:0.005125:0.004294:0.009782:0.009903:0.014182:0.010311:0.003024:0.003024:0.009782:0.010326:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188:0.012150:0.213774
1,2:@0.468805:0.479966:0.480950:0.479966:0.480950:0.470812:0.468805:0.470812:0.004858:0.002429:0.004858
The prevalence of diabetes in south Africa in 2012 was :@0.076185:0.499442:0.485125:0.499442:0.485125:0.483660:0.076185:0.483660:0.006441:0.009223:0.009827:0.004823:0.010311:0.004551:0.009827:0.008376:0.010326:0.003024:0.009827:0.009223:0.009782:0.009827:0.004838:0.009903:0.004747:0.004838:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.004838:0.003024:0.009223:0.004838:0.007529:0.009903:0.009192:0.005125:0.009223:0.004823:0.011188:0.004747:0.004551:0.003024:0.009782:0.010326:0.004838:0.003024:0.009223:0.004838:0.008376:0.008376:0.008376:0.008376:0.004853:0.012564:0.010326:0.005866:0.004188
8% for blacks and whites, 13.4% for coloureds and 30% :@0.076185:0.513620:0.485110:0.513620:0.485110:0.497838:0.076185:0.497838:0.008376:0.011717:0.005322:0.004747:0.009903:0.004551:0.005307:0.010311:0.003024:0.010326:0.009782:0.007590:0.005866:0.005322:0.010326:0.009223:0.010357:0.005307:0.012564:0.009223:0.003024:0.005125:0.009827:0.005866:0.004188:0.005307:0.008376:0.008376:0.004188:0.008376:0.011717:0.005307:0.004747:0.009903:0.004551:0.005307:0.009782:0.009903:0.003024:0.009903:0.009192:0.004551:0.009827:0.010357:0.005866:0.005307:0.010326:0.009223:0.010357:0.005322:0.008376:0.008376:0.011717:0.004188
for the Indian population.:@0.076185:0.527798:0.262225:0.527798:0.262225:0.512015:0.076185:0.512015:0.004747:0.009903:0.004551:0.004188:0.005125:0.009223:0.009827:0.004188:0.003417:0.009223:0.010357:0.003024:0.010326:0.009223:0.004188:0.010311:0.009903:0.010311:0.009192:0.003024:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188
These numbers have major financial implications for :@0.090473:0.541976:0.485140:0.541976:0.485140:0.526193:0.090473:0.526193:0.006441:0.009223:0.009827:0.005866:0.009827:0.006335:0.009223:0.009192:0.014182:0.010311:0.009827:0.004551:0.005866:0.006335:0.009223:0.010326:0.008376:0.009827:0.006350:0.014182:0.010326:0.003069:0.009903:0.004551:0.006335:0.003681:0.003681:0.009223:0.010326:0.009223:0.009782:0.003024:0.010326:0.003024:0.006350:0.003024:0.014182:0.010311:0.003024:0.003024:0.009782:0.010326:0.005125:0.003024:0.009903:0.009223:0.005866:0.006350:0.004747:0.009903:0.004551:0.004188
the future. Many patients with diabetes also suffer from :@0.076185:0.556154:0.485140:0.556154:0.485140:0.540371:0.076185:0.540371:0.005125:0.009223:0.009827:0.004672:0.004747:0.009192:0.005125:0.009192:0.004551:0.009827:0.004188:0.004657:0.013894:0.010326:0.009223:0.008104:0.004672:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004672:0.012564:0.003024:0.005125:0.009223:0.004672:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.004672:0.010326:0.003024:0.005866:0.009903:0.004672:0.005866:0.009192:0.004747:0.004747:0.009827:0.004551:0.004672:0.004747:0.004551:0.009903:0.014182:0.004188
hypertension and lipid disorders (hyperlipidaemia), and :@0.076185:0.570331:0.485140:0.570331:0.485140:0.554549:0.076185:0.554549:0.009223:0.008104:0.010311:0.009827:0.004551:0.005125:0.009827:0.009223:0.005866:0.003024:0.009903:0.009223:0.004369:0.010326:0.009223:0.010357:0.004385:0.003024:0.003024:0.010311:0.003024:0.010357:0.004385:0.010357:0.003024:0.005866:0.009903:0.004551:0.010357:0.009827:0.004551:0.005866:0.004385:0.005579:0.009223:0.008104:0.010311:0.009827:0.004551:0.003024:0.003024:0.010311:0.003024:0.010357:0.010326:0.009827:0.014182:0.003024:0.010326:0.005579:0.004188:0.004400:0.010326:0.009223:0.010357:0.004188
as a group will incur significant healthcare costs in the :@0.076185:0.584509:0.485140:0.584509:0.485140:0.568727:0.076185:0.568727:0.010326:0.005866:0.005488:0.010326:0.005488:0.010175:0.004551:0.009888:0.009192:0.010311:0.005488:0.012564:0.003024:0.003024:0.003039:0.005488:0.003024:0.009223:0.009782:0.009192:0.004551:0.005488:0.005866:0.003024:0.010175:0.009223:0.003024:0.003681:0.003681:0.009782:0.010326:0.009223:0.005125:0.005488:0.009223:0.009827:0.010326:0.003024:0.005125:0.009223:0.009782:0.010326:0.004551:0.009827:0.005473:0.009782:0.009903:0.005866:0.005125:0.005866:0.005488:0.003024:0.009223:0.005488:0.005125:0.009223:0.009827:0.004188
future, especially in the context of an ageing popula-:@0.076185:0.598687:0.480937:0.598687:0.480937:0.582904:0.076185:0.582904:0.004747:0.009192:0.005125:0.009192:0.004551:0.009827:0.004188:0.005881:0.009827:0.005866:0.010311:0.009827:0.009782:0.003024:0.010326:0.003024:0.003024:0.008104:0.005912:0.003024:0.009223:0.005896:0.005125:0.009223:0.009827:0.005881:0.009782:0.009903:0.009223:0.005125:0.009827:0.007257:0.005125:0.005881:0.009903:0.004747:0.005881:0.010326:0.009223:0.005896:0.010326:0.010175:0.009827:0.003024:0.009223:0.010175:0.005881:0.010311:0.009903:0.010311:0.009192:0.003024:0.010326:0.005020
tion. These factors add to the challenge of comorbid :@0.076185:0.612865:0.485125:0.612865:0.485125:0.597082:0.076185:0.597082:0.005125:0.003024:0.009903:0.009223:0.004188:0.006305:0.006441:0.009223:0.009827:0.005866:0.009827:0.006305:0.004747:0.010326:0.009782:0.005125:0.009903:0.004551:0.005866:0.006305:0.010326:0.010357:0.010357:0.006320:0.005125:0.009903:0.006305:0.005125:0.009223:0.009827:0.006320:0.009782:0.009223:0.010326:0.003024:0.003024:0.009827:0.009223:0.010175:0.009827:0.006305:0.009903:0.004747:0.006305:0.009782:0.009903:0.014182:0.009903:0.004551:0.010311:0.003024:0.010357:0.004188
conditions. As complications develop, the costs similarly :@0.076185:0.627043:0.485125:0.627043:0.485125:0.611260:0.076185:0.611260:0.009782:0.009903:0.009223:0.010357:0.003024:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188:0.003825:0.011188:0.005866:0.003825:0.009782:0.009903:0.014182:0.010311:0.003024:0.003024:0.009782:0.010326:0.005125:0.003024:0.009903:0.009223:0.005866:0.003825:0.010357:0.009827:0.008376:0.009827:0.003024:0.009903:0.010311:0.004188:0.003825:0.005125:0.009223:0.009827:0.003825:0.009782:0.009903:0.005866:0.005125:0.005866:0.003825:0.005866:0.003024:0.014182:0.003024:0.003024:0.010326:0.004551:0.003024:0.008104:0.004188
escalate – for example, heart failure and end-stage re-:@0.076185:0.641220:0.480952:0.641220:0.480952:0.625438:0.076185:0.625438:0.009827:0.005866:0.009782:0.010326:0.003024:0.010326:0.005125:0.009827:0.004521:0.007560:0.004521:0.004747:0.009903:0.004551:0.004521:0.009827:0.007257:0.010326:0.014182:0.010311:0.003024:0.009827:0.004188:0.004521:0.009223:0.009827:0.010326:0.004551:0.005125:0.004521:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004521:0.010326:0.009223:0.010357:0.004521:0.009827:0.009223:0.010357:0.005020:0.005866:0.005125:0.010326:0.010175:0.009827:0.004521:0.004551:0.009827:0.005020
nal disease. :@0.076185:0.655398:0.166416:0.655398:0.166416:0.639616:0.076185:0.639616:0.009223:0.010326:0.003024:0.004188:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.004188:0.004188
tHe CArDiOmetAbOliC AnD renAl interseCt:@0.076190:0.688349:0.478290:0.688349:0.478290:0.668184:0.076190:0.668184:0.007576:0.012381:0.009424:0.004989:0.014229:0.013490:0.010533:0.012750:0.004989:0.015337:0.016446:0.009424:0.007576:0.013490:0.010533:0.015337:0.007946:0.004989:0.014229:0.004989:0.013490:0.013490:0.012750:0.004989:0.010533:0.009424:0.013490:0.013490:0.007946:0.004989:0.004989:0.013490:0.007576:0.009424:0.010533:0.009424:0.009424:0.014229:0.007761
The role of renal dysfunction in patients suffering from :@0.076190:0.704307:0.485130:0.704307:0.485130:0.688524:0.076190:0.688524:0.006441:0.009223:0.009827:0.006244:0.004551:0.009903:0.003024:0.009827:0.006244:0.009903:0.004747:0.006244:0.004551:0.009827:0.009223:0.010326:0.003024:0.006259:0.010357:0.008104:0.005866:0.004747:0.009192:0.009223:0.009782:0.005125:0.003024:0.009903:0.009223:0.006244:0.003024:0.009223:0.006259:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.006259:0.005866:0.009192:0.004747:0.004747:0.009827:0.004551:0.003024:0.009223:0.010175:0.006244:0.004747:0.004551:0.009903:0.014182:0.004188
cardiovascular disease has  been  highlighted  by re-:@0.076190:0.718484:0.480957:0.718484:0.480957:0.702702:0.076190:0.702702:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.009253:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.009253:0.009223:0.010326:0.005866:0.004188:0.005050:0.010311:0.009827:0.009827:0.009223:0.004188:0.005050:0.009223:0.003024:0.010175:0.009223:0.003024:0.003024:0.010175:0.009223:0.005125:0.009827:0.010357:0.004188:0.005050:0.010311:0.008104:0.009253:0.004551:0.009827:0.005020
search relating to the sGLT2 inhibitor class of anti-dia-:@0.076190:0.732662:0.480972:0.732662:0.480972:0.716880:0.076190:0.716880:0.005866:0.009827:0.010326:0.004551:0.009782:0.009223:0.006229:0.004551:0.009827:0.003024:0.010326:0.005125:0.003024:0.009223:0.010175:0.006229:0.005125:0.009903:0.006229:0.005125:0.009223:0.009827:0.006229:0.007529:0.013184:0.006985:0.006441:0.008376:0.006229:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.006229:0.009782:0.003024:0.010326:0.005866:0.005866:0.006244:0.009903:0.004747:0.006229:0.010326:0.009223:0.005125:0.003024:0.005020:0.010357:0.003024:0.010326:0.005020
betic agents, as well as by new insights gained from the :@0.076190:0.746840:0.485160:0.746840:0.485160:0.731057:0.076190:0.731057:0.010311:0.009827:0.005125:0.003024:0.009782:0.003916:0.010326:0.010175:0.009827:0.009223:0.005125:0.005866:0.004188:0.003901:0.010326:0.005866:0.003916:0.012564:0.009827:0.003024:0.003024:0.003916:0.010326:0.005866:0.003916:0.010311:0.008104:0.003916:0.009223:0.009827:0.012564:0.003901:0.003024:0.009223:0.005866:0.003024:0.010175:0.009223:0.005125:0.005866:0.003916:0.010175:0.010326:0.003024:0.009223:0.009827:0.010357:0.003916:0.004747:0.004551:0.009903:0.014182:0.003901:0.005125:0.009223:0.009827:0.004188
development of the RAAs inhibitor, and the combina-:@0.076190:0.761018:0.480957:0.761018:0.480957:0.745235:0.076190:0.745235:0.010357:0.009827:0.008376:0.009827:0.003024:0.009903:0.010311:0.014182:0.009827:0.009223:0.005125:0.005639:0.009903:0.004747:0.005639:0.005125:0.009223:0.009827:0.005624:0.009177:0.011188:0.011188:0.007529:0.005624:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.004188:0.005639:0.010326:0.009223:0.010357:0.005639:0.005125:0.009223:0.009827:0.005624:0.009782:0.009903:0.014182:0.010311:0.003024:0.009223:0.010326:0.005020
tion of valsartan, the neprilysin inhibitors and sacubitril :@0.076190:0.775196:0.485115:0.775196:0.485115:0.759413:0.076190:0.759413:0.005125:0.003024:0.009903:0.009223:0.006244:0.009903:0.004747:0.006244:0.008376:0.010326:0.003024:0.005866:0.010326:0.004551:0.005125:0.010341:0.009223:0.004188:0.006244:0.005125:0.009223:0.009827:0.006244:0.009223:0.009827:0.010311:0.004551:0.003024:0.003024:0.008104:0.005866:0.003024:0.009223:0.006244:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.006244:0.010326:0.009223:0.010357:0.006244:0.005866:0.010326:0.009782:0.009192:0.010311:0.003024:0.005125:0.004551:0.003024:0.003024:0.004188
for the management of heart failure.:@0.076190:0.789373:0.345506:0.789373:0.345506:0.773591:0.076190:0.773591:0.004747:0.009903:0.004551:0.004188:0.005125:0.009223:0.009827:0.004188:0.014182:0.010326:0.009223:0.010326:0.010175:0.009827:0.014182:0.009827:0.009223:0.005125:0.004188:0.009903:0.004747:0.004188:0.009223:0.009827:0.010326:0.004551:0.005125:0.004188:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004188
The presence of renal dysfunction in diabetes and :@0.090478:0.803551:0.485145:0.803551:0.485145:0.787769:0.090478:0.787769:0.006441:0.009223:0.009827:0.007544:0.010311:0.004551:0.009827:0.005866:0.009827:0.009223:0.009782:0.009827:0.007544:0.009903:0.004747:0.007544:0.004551:0.009827:0.009223:0.010326:0.003024:0.007544:0.010357:0.008104:0.005866:0.004747:0.009192:0.009223:0.009782:0.005125:0.003024:0.009903:0.009223:0.007544:0.003024:0.009223:0.007544:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.007544:0.010326:0.009223:0.010357:0.004188
cardiovascular disease implies accelerated atheroscle-:@0.076190:0.817729:0.480957:0.817729:0.480957:0.801946:0.076190:0.801946:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.003946:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.003946:0.003024:0.014182:0.010311:0.003024:0.003024:0.009827:0.005866:0.003961:0.010326:0.009782:0.009782:0.009827:0.003024:0.009827:0.004551:0.010326:0.005125:0.009827:0.010357:0.003946:0.010326:0.005125:0.009223:0.009827:0.004551:0.009903:0.005866:0.009782:0.003024:0.009827:0.005020
rosis and premature vascular ageing.  The prevalence :@0.076190:0.831907:0.485115:0.831907:0.485115:0.816124:0.076190:0.816124:0.004551:0.009903:0.005866:0.003024:0.005866:0.006471:0.010326:0.009223:0.010357:0.006471:0.010311:0.004551:0.009827:0.014182:0.010326:0.005125:0.009192:0.004551:0.009827:0.006456:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.006471:0.010326:0.010175:0.009827:0.003024:0.009223:0.010175:0.004188:0.004188:0.002268:0.006441:0.009223:0.009827:0.006456:0.010311:0.004551:0.009827:0.008376:0.010326:0.003024:0.009827:0.009223:0.009782:0.009827:0.004188
of hypertension in patients with impaired glucose tole-:@0.076190:0.846085:0.480942:0.846085:0.480942:0.830302:0.076190:0.830302:0.009903:0.004747:0.005518:0.009223:0.008104:0.010311:0.009827:0.004551:0.005125:0.009827:0.009223:0.005866:0.003024:0.009903:0.009207:0.005518:0.003024:0.009223:0.005518:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.005518:0.012564:0.003024:0.005125:0.009223:0.005518:0.003024:0.014182:0.010311:0.010326:0.003024:0.004551:0.009827:0.010357:0.005518:0.010175:0.003024:0.009192:0.009782:0.009903:0.005866:0.009827:0.005518:0.005125:0.009903:0.003024:0.009827:0.005020
rance is 60,2%, but as high as 79,4% in those with con-:@0.076190:0.860262:0.480942:0.860262:0.480942:0.844480:0.076190:0.844480:0.004551:0.010326:0.009223:0.009782:0.009827:0.005564:0.003024:0.005866:0.005564:0.008376:0.008376:0.004188:0.008376:0.011717:0.004188:0.005564:0.010311:0.009192:0.005125:0.005564:0.010326:0.005866:0.005564:0.009223:0.003024:0.010175:0.009223:0.005564:0.010326:0.005866:0.005564:0.008376:0.008376:0.004188:0.008376:0.011717:0.005564:0.003024:0.009223:0.005564:0.005125:0.009223:0.009903:0.005866:0.009827:0.005549:0.012564:0.003024:0.005125:0.009223:0.005564:0.009782:0.009903:0.009223:0.005020
comitant  diabetes. This  represents  the  need  for  treat-:@0.076190:0.874440:0.480957:0.874440:0.480957:0.858658:0.076190:0.858658:0.009782:0.009903:0.014182:0.003024:0.005125:0.010326:0.009223:0.005125:0.004188:0.002540:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.004188:0.006743:0.006441:0.009223:0.003024:0.005866:0.004188:0.002540:0.004551:0.009827:0.010311:0.004551:0.009827:0.005866:0.009827:0.009223:0.005125:0.005866:0.004188:0.002540:0.005125:0.009223:0.009827:0.004188:0.002540:0.009223:0.009827:0.009827:0.010357:0.004188:0.002540:0.004747:0.009903:0.004551:0.004188:0.002540:0.005125:0.004551:0.009827:0.010326:0.005125:0.005020
ment  that will protect  against end-organ  damage in :@0.076190:0.888618:0.485130:0.888618:0.485130:0.872835:0.076190:0.872835:0.014182:0.009827:0.009223:0.005125:0.004188:0.002978:0.005125:0.009223:0.010326:0.005125:0.007182:0.012564:0.003024:0.003024:0.003024:0.007182:0.010311:0.004551:0.009903:0.005125:0.009827:0.009782:0.005125:0.004188:0.002978:0.010326:0.010175:0.010326:0.003024:0.009223:0.005866:0.005125:0.007182:0.009827:0.009223:0.010357:0.005020:0.009903:0.004551:0.010175:0.010326:0.009223:0.004188:0.002978:0.010357:0.010326:0.014182:0.010326:0.010175:0.009827:0.007182:0.003024:0.009223:0.004188
addition  to  being  metabolically favourable.   For  this :@0.076190:0.902796:0.485136:0.902823:0.485136:0.887041:0.076190:0.887013:0.010326:0.010357:0.010357:0.003024:0.005125:0.003024:0.009903:0.009223:0.004188:0.004339:0.005125:0.009903:0.004188:0.004339:0.010311:0.009827:0.003024:0.009223:0.010175:0.004188:0.004339:0.014182:0.009827:0.005125:0.010326:0.010311:0.009903:0.003024:0.003024:0.009782:0.010326:0.003024:0.003024:0.008104:0.008542:0.004747:0.010326:0.008376:0.009903:0.009192:0.004551:0.010326:0.010311:0.003024:0.009827:0.004188:0.004874:0.004188:0.004339:0.007333:0.009903:0.004551:0.004188:0.004339:0.005125:0.009223:0.003024:0.005866:-0.333025
5:@0.414009:0.897525:0.418867:0.897525:0.418867:0.888371:0.414009:0.888371:0.004858
reason, the  sEMDsA guideline selected indapamide, :@0.076196:0.917001:0.485136:0.917001:0.485136:0.901218:0.076196:0.901218:0.004551:0.009827:0.010326:0.005866:0.009903:0.009223:0.004188:0.008149:0.005125:0.009223:0.009827:0.004188:0.003961:0.007529:0.008104:0.013894:0.011249:0.007529:0.011188:0.008149:0.010175:0.009192:0.003024:0.010357:0.009827:0.003024:0.003024:0.009223:0.009827:0.008149:0.005866:0.009827:0.003024:0.009827:0.009782:0.005125:0.009827:0.010357:0.008149:0.003024:0.009223:0.010357:0.010326:0.010311:0.010326:0.014182:0.003024:0.010357:0.009827:0.004188:0.004188
as opposed to  hydrochlorothiazide, as the  diuretic  of :@0.076196:0.931179:0.485166:0.931179:0.485166:0.915396:0.076196:0.915396:0.010326:0.005866:0.006743:0.009903:0.010311:0.010311:0.009903:0.005866:0.009827:0.010357:0.006743:0.005125:0.009903:0.004188:0.002540:0.009223:0.008104:0.010357:0.004551:0.009903:0.009782:0.009223:0.003024:0.009903:0.004551:0.009903:0.005125:0.009207:0.003024:0.010326:0.006426:0.003024:0.010357:0.009827:0.004188:0.006743:0.010326:0.005866:0.006743:0.005125:0.009223:0.009827:0.004188:0.002540:0.010357:0.003024:0.009192:0.004551:0.009827:0.005125:0.003024:0.009782:0.004188:0.002540:0.009903:0.004747:0.004188
choice.  :@0.076196:0.945357:0.140960:0.945363:0.140960:0.929580:0.076196:0.929574:0.009782:0.009223:0.009903:0.003024:0.009782:0.009827:0.004188:0.004847:-0.044555
3:@0.131912:0.940064:0.136770:0.940064:0.136770:0.930910:0.131912:0.930910:0.004858
In keeping with international and national guidelines, :@0.533329:0.168573:0.927997:0.168573:0.927997:0.152791:0.533329:0.152791:0.003417:0.009223:0.004702:0.007590:0.009827:0.009827:0.010311:0.003024:0.009223:0.010175:0.004702:0.012564:0.003024:0.005125:0.009223:0.004702:0.003024:0.009223:0.005125:0.009827:0.004551:0.009223:0.010326:0.005125:0.003024:0.009903:0.009223:0.010326:0.003024:0.004687:0.010326:0.009223:0.010357:0.004702:0.009223:0.010326:0.005125:0.003024:0.009903:0.009223:0.010326:0.003024:0.004702:0.010175:0.009192:0.003024:0.010357:0.009827:0.003024:0.003024:0.009223:0.009827:0.005866:0.004188:0.004188
RAAs  blockers  (ACE  inhibitors  and  ARBs) should  be :@0.519042:0.182959:0.927966:0.182959:0.927966:0.167176:0.519042:0.167176:0.009177:0.011188:0.011188:0.007529:0.004188:0.005277:0.010311:0.003024:0.009903:0.009782:0.007590:0.009827:0.004551:0.005866:0.004188:0.005277:0.005579:0.011188:0.012292:0.008104:0.004188:0.005277:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.004188:0.005277:0.010326:0.009223:0.010357:0.004188:0.005277:0.011188:0.009177:0.008678:0.005866:0.005579:0.009480:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.004188:0.005277:0.010311:0.009827:0.004188
combined  with calcium-channel  blockers  as therapy :@0.519042:0.197345:0.927981:0.197345:0.927981:0.181562:0.519042:0.181562:0.009782:0.009903:0.014182:0.010311:0.003024:0.009223:0.009827:0.010357:0.004188:0.003553:0.012564:0.003024:0.005125:0.009223:0.007756:0.009782:0.010326:0.003024:0.009782:0.003024:0.009192:0.014182:0.005020:0.009782:0.009223:0.010326:0.009223:0.009223:0.009827:0.003024:0.004188:0.003553:0.010311:0.003024:0.009903:0.009782:0.007590:0.009827:0.004551:0.005866:0.004188:0.003553:0.010326:0.005866:0.007756:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004188
for hypertension, whether the patient is diabetic or not.  :@0.519042:0.211730:0.927997:0.211723:0.927997:0.195940:0.519042:0.195948:0.004747:0.009903:0.004551:0.003901:0.009223:0.008104:0.010311:0.009827:0.004551:0.005125:0.009827:0.009223:0.005866:0.003024:0.009903:0.009223:0.004188:0.003916:0.012564:0.009223:0.009827:0.005125:0.009223:0.009827:0.004551:0.003901:0.005125:0.009223:0.009827:0.003901:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.003916:0.003024:0.005866:0.003916:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.003024:0.009782:0.003916:0.009903:0.004551:0.003901:0.009223:0.009903:0.005125:0.004188:0.004869:0.129126
4:@0.918949:0.206424:0.923807:0.206424:0.923807:0.197270:0.918949:0.197270:0.004858
The blood-pressure targets have been adjusted to ac-:@0.519042:0.226108:0.923794:0.226108:0.923794:0.210326:0.519042:0.210326:0.006441:0.009223:0.009827:0.005503:0.010311:0.003024:0.009903:0.009903:0.010357:0.005020:0.010311:0.004551:0.009827:0.005866:0.005866:0.009192:0.004551:0.009827:0.005503:0.005125:0.010326:0.004551:0.010175:0.009827:0.005125:0.005866:0.005503:0.009223:0.010326:0.008376:0.009827:0.005503:0.010311:0.009827:0.009827:0.009223:0.005503:0.010326:0.010357:0.003069:0.009192:0.005866:0.005125:0.009827:0.010357:0.005518:0.005125:0.009903:0.005503:0.010326:0.009782:0.005020
count for age and comorbidities. The risk of excessive :@0.519042:0.240494:0.927982:0.240494:0.927982:0.224711:0.519042:0.224711:0.009782:0.009903:0.009192:0.009223:0.005125:0.006017:0.004747:0.009903:0.004551:0.006017:0.010326:0.010175:0.009827:0.006032:0.010326:0.009223:0.010357:0.006032:0.009782:0.009903:0.014182:0.009903:0.004551:0.010311:0.003024:0.010357:0.003024:0.005125:0.003024:0.009827:0.005866:0.004188:0.006032:0.006441:0.009223:0.009827:0.006017:0.004551:0.003024:0.005866:0.007590:0.006032:0.009903:0.004747:0.006017:0.009827:0.007257:0.009782:0.009827:0.005866:0.005866:0.003024:0.008376:0.009827:0.004188
blood-pressure reduction has become clear, especial-:@0.519042:0.254880:0.923809:0.254880:0.923809:0.239097:0.519042:0.239097:0.010311:0.003024:0.009903:0.009903:0.010357:0.005020:0.010311:0.004551:0.009827:0.005866:0.005866:0.009192:0.004551:0.009827:0.005458:0.004551:0.009827:0.010357:0.009192:0.009782:0.005125:0.003024:0.009903:0.009223:0.005458:0.009223:0.010326:0.005866:0.005473:0.010311:0.009827:0.009782:0.009903:0.014182:0.009827:0.005458:0.009782:0.003024:0.009827:0.010326:0.004551:0.004188:0.005458:0.009827:0.005866:0.010311:0.009827:0.009782:0.003024:0.010326:0.003039:0.005020
ly the risk of falls and postural hypotension. The spRINT :@0.519042:0.269265:0.927997:0.269265:0.927997:0.253483:0.519042:0.253483:0.003024:0.008104:0.005836:0.005125:0.009223:0.009827:0.005836:0.004551:0.003024:0.005866:0.007590:0.005836:0.009903:0.004747:0.005821:0.004747:0.010326:0.003024:0.003024:0.005866:0.005836:0.010326:0.009223:0.010357:0.005836:0.010311:0.009903:0.005866:0.005125:0.009192:0.004551:0.010326:0.003024:0.005836:0.009223:0.008104:0.010311:0.009903:0.005125:0.009827:0.009223:0.005866:0.003024:0.009903:0.009223:0.004188:0.005821:0.006441:0.009223:0.009827:0.005821:0.007529:0.008950:0.009177:0.003417:0.011188:0.006441:0.004188
study  found  that  the  greatest  cardiovascular  benefits :@0.519042:0.283651:0.928012:0.283651:0.928012:0.267868:0.519042:0.267868:0.005866:0.005125:0.009192:0.010357:0.008104:0.004188:0.002646:0.004747:0.009903:0.009192:0.009223:0.010357:0.004188:0.002646:0.005125:0.009223:0.010326:0.005125:0.004188:0.002646:0.005125:0.009223:0.009827:0.004188:0.002631:0.010175:0.004551:0.009827:0.010326:0.005125:0.009827:0.005866:0.005125:0.004188:0.002646:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.004188:0.002646:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.005125:0.005866:0.004188
were achieved with systolic blood pressure <132 mmHg. :@0.519042:0.298037:0.927997:0.298037:0.927997:0.282254:0.519042:0.282254:0.012564:0.009827:0.004551:0.009827:0.003674:0.010326:0.009782:0.009223:0.003024:0.009827:0.008376:0.009827:0.010357:0.003689:0.012564:0.003024:0.005125:0.009223:0.003689:0.005866:0.008104:0.005866:0.005125:0.009903:0.003024:0.003024:0.009782:0.003689:0.010311:0.003024:0.009903:0.009903:0.010357:0.003674:0.010311:0.004551:0.009827:0.005866:0.005866:0.009192:0.004551:0.009827:0.003674:0.009162:0.008376:0.008376:0.008376:0.003704:0.014182:0.014182:0.010326:0.010175:0.004188:0.004188
The trial was stopped early as there was a clear mortal-:@0.519042:0.312422:0.923824:0.312422:0.923824:0.296640:0.519042:0.296640:0.006441:0.009223:0.009827:0.004339:0.005125:0.004551:0.003024:0.010326:0.003024:0.004339:0.012564:0.010326:0.005866:0.004354:0.005866:0.005125:0.009903:0.010311:0.010311:0.009827:0.010357:0.004354:0.009827:0.010326:0.004551:0.003024:0.008104:0.004354:0.010326:0.005866:0.004354:0.005125:0.009223:0.009827:0.004551:0.009827:0.004339:0.012564:0.010326:0.005866:0.004354:0.010326:0.004354:0.009782:0.003024:0.009827:0.010326:0.004551:0.004339:0.014182:0.009903:0.004551:0.005125:0.010326:0.003024:0.005020
ity benefit in the intensive treatment arm.:@0.519042:0.326808:0.818596:0.326808:0.818596:0.311025:0.519042:0.311025:0.003024:0.005125:0.008104:0.004188:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.005125:0.004188:0.003024:0.009223:0.004188:0.005125:0.009223:0.009827:0.004188:0.003024:0.009223:0.005125:0.009827:0.009223:0.005866:0.003024:0.008376:0.009827:0.004188:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.004188:0.010326:0.004551:0.014182:0.004188
6:@0.818564:0.321505:0.823422:0.321505:0.823422:0.312351:0.818564:0.312351:0.004858
 The sA Hypertension society guidelines echo interna-:@0.533333:0.341189:0.923812:0.341189:0.923812:0.325406:0.533333:0.325406:0.004158:0.006441:0.009223:0.009827:0.004158:0.007529:0.011188:0.004158:0.010326:0.008104:0.010311:0.009827:0.004551:0.005125:0.009827:0.009223:0.005866:0.003024:0.009903:0.009223:0.004158:0.007529:0.009903:0.009782:0.003024:0.009827:0.005125:0.008104:0.004158:0.010175:0.009192:0.003024:0.010357:0.009827:0.003024:0.003024:0.009223:0.009827:0.005866:0.004158:0.009827:0.009782:0.009223:0.009903:0.004143:0.003024:0.009223:0.005125:0.009827:0.004551:0.009223:0.010311:0.005020
tional guidelines in that they advocate to keep blood :@0.519045:0.355574:0.928000:0.355574:0.928000:0.339792:0.519045:0.339792:0.005125:0.003024:0.009903:0.009223:0.010326:0.003024:0.005775:0.010175:0.009192:0.003024:0.010357:0.009827:0.003024:0.003024:0.009223:0.009827:0.005866:0.005775:0.003024:0.009223:0.005775:0.005125:0.009223:0.010326:0.005125:0.005760:0.005125:0.009223:0.009827:0.008104:0.005775:0.010326:0.010357:0.008376:0.009903:0.009782:0.010326:0.005125:0.009827:0.005775:0.005125:0.009903:0.005760:0.007590:0.009827:0.009827:0.010311:0.005775:0.010311:0.003024:0.009903:0.009903:0.010357:0.004188
pressure below 130/80 mm Hg, to treat if blood pressure :@0.519045:0.369960:0.928000:0.369960:0.928000:0.354177:0.519045:0.354177:0.010311:0.004551:0.009827:0.005866:0.005866:0.009192:0.004551:0.009827:0.004037:0.010311:0.009827:0.003024:0.009903:0.012564:0.004037:0.008376:0.008376:0.008376:0.006607:0.008376:0.008376:0.004067:0.014182:0.014182:0.004037:0.010326:0.010175:0.004188:0.004037:0.005125:0.009903:0.004037:0.005125:0.004551:0.009827:0.010326:0.005125:0.004037:0.003024:0.004747:0.004037:0.010311:0.003024:0.009903:0.009903:0.010357:0.004037:0.010311:0.004551:0.009827:0.005866:0.005866:0.009192:0.004551:0.009827:0.004188
is >140/90  mmHg and to  avoid lowering  blood pres-:@0.519045:0.384346:0.923797:0.384346:0.923797:0.368563:0.519045:0.368563:0.003024:0.005866:0.007635:0.009162:0.008376:0.008376:0.008376:0.006607:0.008376:0.008376:0.004188:0.003462:0.014182:0.014182:0.010326:0.010175:0.007635:0.010326:0.009223:0.010357:0.007635:0.005125:0.009903:0.004188:0.003432:0.010326:0.008376:0.009903:0.003024:0.010357:0.007635:0.003024:0.009903:0.012564:0.009827:0.004551:0.003024:0.009223:0.010175:0.004188:0.003432:0.010311:0.003024:0.009903:0.009903:0.010357:0.007635:0.010311:0.004551:0.009827:0.005866:0.005020
sure below 120 mmHg systolic in the elderly (>65 years :@0.519045:0.398731:0.927985:0.398731:0.927985:0.382949:0.519045:0.382949:0.005866:0.009192:0.004551:0.009827:0.005518:0.010311:0.009827:0.003024:0.009903:0.012564:0.005518:0.008376:0.008376:0.008391:0.005518:0.014182:0.014182:0.010326:0.010175:0.005518:0.005866:0.008104:0.005866:0.005125:0.009903:0.003024:0.003024:0.009782:0.005518:0.003024:0.009223:0.005518:0.005125:0.009223:0.009827:0.005518:0.009827:0.003024:0.010357:0.009827:0.004551:0.003024:0.008104:0.005518:0.005579:0.009162:0.008376:0.008376:0.005534:0.008104:0.009827:0.010326:0.004551:0.005866:0.004188
of age). The same targets apply  in diabetes  mellitus, :@0.519045:0.413117:0.927985:0.413117:0.927985:0.397334:0.519045:0.397334:0.009903:0.004747:0.007106:0.010326:0.010175:0.009827:0.005579:0.004188:0.007106:0.006441:0.009223:0.009827:0.007106:0.005866:0.010326:0.014182:0.009827:0.007106:0.005125:0.010326:0.004551:0.010175:0.009827:0.005125:0.005866:0.007106:0.010326:0.010311:0.010311:0.003024:0.008104:0.004188:0.002933:0.003024:0.009223:0.007106:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.004188:0.002933:0.014182:0.009827:0.003024:0.003024:0.003024:0.005125:0.009192:0.005866:0.004188:0.004188
with the preferred  drug classes  being RAAs blockers, :@0.519045:0.427503:0.928000:0.427503:0.928000:0.411720:0.519045:0.411720:0.012564:0.003024:0.005125:0.009223:0.007227:0.005125:0.009223:0.009827:0.007227:0.010311:0.004551:0.009827:0.004747:0.009827:0.004551:0.004551:0.009827:0.010357:0.004188:0.003024:0.010357:0.004551:0.009192:0.010175:0.007227:0.009782:0.003024:0.010326:0.005866:0.005866:0.009827:0.005866:0.004188:0.003054:0.010311:0.009827:0.003024:0.009223:0.010175:0.007227:0.009177:0.011188:0.011188:0.007529:0.007227:0.010311:0.003024:0.009903:0.009782:0.007590:0.009827:0.004551:0.005866:0.004188:0.004188
thiazide-like diuretics  (indapamide) and  non-dihydro-:@0.519045:0.441888:0.923812:0.441888:0.923812:0.426106:0.519045:0.426106:0.005125:0.009223:0.003024:0.010326:0.006426:0.003024:0.010357:0.009827:0.005020:0.003024:0.003024:0.007590:0.009827:0.008074:0.010357:0.003024:0.009192:0.004551:0.009827:0.005125:0.003024:0.009782:0.005866:0.004188:0.003870:0.005579:0.003024:0.009223:0.010357:0.010326:0.010311:0.010326:0.014182:0.003024:0.010357:0.009827:0.005579:0.008074:0.010326:0.009223:0.010357:0.004188:0.003870:0.009223:0.009903:0.009223:0.005020:0.010357:0.003024:0.009223:0.008104:0.010357:0.004551:0.009918:0.005020
pyridine CCBs (verapamil, diltiazem).  :@0.519045:0.456274:0.797019:0.456270:0.797019:0.440487:0.519045:0.440491:0.010311:0.008104:0.004551:0.003024:0.010357:0.003024:0.009223:0.009827:0.004188:0.012292:0.012292:0.008678:0.005866:0.004188:0.005579:0.008376:0.009827:0.004551:0.010326:0.010311:0.010326:0.014182:0.003024:0.003024:0.004188:0.004188:0.010357:0.003024:0.003024:0.005125:0.003024:0.010326:0.006426:0.009827:0.014182:0.005579:0.004188:0.004878:-0.060135
3:@0.787971:0.450971:0.792829:0.450971:0.792829:0.441817:0.787971:0.441817:0.004858
The addition of Dpp-4 inhibitors (vildagliptin, sitaglip-:@0.533328:0.470655:0.923807:0.470655:0.923807:0.454873:0.533328:0.454873:0.006441:0.009223:0.009827:0.006410:0.010326:0.010357:0.010357:0.003024:0.005125:0.003024:0.009903:0.009223:0.006410:0.009903:0.004747:0.006410:0.011249:0.008950:0.008950:0.005020:0.008376:0.006410:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.006410:0.005579:0.008376:0.003024:0.003024:0.010357:0.010326:0.010175:0.003024:0.003024:0.010311:0.005125:0.003024:0.009223:0.004188:0.006426:0.005866:0.003024:0.005125:0.010326:0.010175:0.003024:0.003024:0.010341:0.005020
tin and saxagliptin) has broadened the management :@0.519040:0.485041:0.928010:0.485041:0.928010:0.469258:0.519040:0.469258:0.005125:0.003024:0.009223:0.006259:0.010326:0.009223:0.010357:0.006259:0.005866:0.010326:0.007257:0.010326:0.010175:0.003024:0.003039:0.010311:0.005125:0.003024:0.009223:0.005579:0.006259:0.009223:0.010326:0.005866:0.006259:0.010311:0.004551:0.009903:0.010326:0.010357:0.009827:0.009223:0.009827:0.010357:0.006259:0.005125:0.009223:0.009827:0.006244:0.014182:0.010326:0.009223:0.010326:0.010175:0.009827:0.014182:0.009827:0.009223:0.005125:0.004188
of type II diabetes. several studies have demonstrated :@0.519040:0.499426:0.927995:0.499426:0.927995:0.483644:0.519040:0.483644:0.009903:0.004747:0.005125:0.005125:0.008104:0.010311:0.009827:0.005125:0.003417:0.003417:0.005140:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.004188:0.005140:0.007529:0.009827:0.008376:0.009827:0.004551:0.010326:0.003024:0.005125:0.005866:0.005125:0.009192:0.010357:0.003024:0.009827:0.005866:0.005140:0.009223:0.010326:0.008376:0.009827:0.005125:0.010357:0.009827:0.014182:0.009903:0.009223:0.005866:0.005125:0.004551:0.010326:0.005125:0.009827:0.010357:0.004188
their cardiovascular (CV) safety, and these drugs pro-:@0.519040:0.513812:0.923792:0.513812:0.923792:0.498029:0.519040:0.498029:0.005125:0.009223:0.009827:0.003024:0.004551:0.005942:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.005957:0.005579:0.012292:0.010614:0.005579:0.005957:0.005866:0.010326:0.004747:0.009827:0.005125:0.008104:0.004188:0.005957:0.010326:0.009223:0.010357:0.005957:0.005125:0.009223:0.009827:0.005866:0.009827:0.005942:0.010357:0.004551:0.009192:0.010175:0.005866:0.005957:0.010311:0.004551:0.009903:0.005020
vide excellent glucose control when used in combina-:@0.519040:0.528198:0.923792:0.528198:0.923792:0.512415:0.519040:0.512415:0.008376:0.003024:0.010357:0.009827:0.005277:0.009827:0.007257:0.009782:0.009827:0.003024:0.003024:0.009827:0.009223:0.005125:0.005261:0.010175:0.003024:0.009192:0.009782:0.009903:0.005866:0.009827:0.005261:0.009782:0.009903:0.009223:0.005125:0.004551:0.009903:0.003024:0.005261:0.012564:0.009223:0.009827:0.009223:0.005261:0.009192:0.005866:0.009827:0.010357:0.005277:0.003024:0.009223:0.005277:0.009782:0.009903:0.014182:0.010311:0.003024:0.009223:0.010326:0.005020
tion with metformin. They can also be added to other :@0.519040:0.542583:0.928010:0.542583:0.928010:0.526801:0.519040:0.526801:0.005125:0.003024:0.009903:0.009223:0.005730:0.012564:0.003024:0.005125:0.009223:0.005730:0.014182:0.009827:0.005125:0.004747:0.009888:0.004551:0.014182:0.003024:0.009223:0.004188:0.005730:0.006441:0.009223:0.009827:0.008104:0.005730:0.009782:0.010326:0.009223:0.005730:0.010326:0.003024:0.005866:0.009903:0.005730:0.010311:0.009827:0.005730:0.010326:0.010357:0.010357:0.009827:0.010357:0.005730:0.005125:0.009903:0.005730:0.009903:0.005125:0.009223:0.009827:0.004551:0.004188
oral, as well as injectable, diabetic treatments.:@0.519040:0.556969:0.867292:0.556969:0.867292:0.541186:0.519040:0.541186:0.009903:0.004551:0.010326:0.003024:0.004188:0.005428:0.010326:0.005866:0.005428:0.012564:0.009827:0.003024:0.003024:0.005428:0.010326:0.005866:0.005428:0.003024:0.009223:0.003069:0.009827:0.009782:0.005125:0.010326:0.010311:0.003024:0.009827:0.004188:0.005428:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.003024:0.009782:0.005428:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.005866:0.004188
9-11:@0.867301:0.551666:0.884787:0.551666:0.884787:0.542513:0.867301:0.542513:0.004858:0.002911:0.004858:0.004858
 They :@0.884792:0.556965:0.928002:0.556965:0.928002:0.541182:0.884792:0.541182:0.005428:0.006441:0.009223:0.009827:0.008104:0.004188
have the benefit of posing low hypoglycaemic risk and :@0.519047:0.571351:0.927987:0.571351:0.927987:0.555568:0.519047:0.555568:0.009223:0.010326:0.008376:0.009827:0.004475:0.005125:0.009223:0.009827:0.004475:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.005125:0.004475:0.009903:0.004747:0.004475:0.010311:0.009903:0.005866:0.003024:0.009223:0.010175:0.004475:0.003024:0.009903:0.012564:0.004475:0.009223:0.008104:0.010311:0.009903:0.010175:0.003024:0.008104:0.009782:0.010326:0.009827:0.014182:0.003024:0.009782:0.004475:0.004551:0.003024:0.005866:0.007590:0.004475:0.010326:0.009223:0.010357:0.004188
are weight-neutral. There was, however, a potential :@0.519047:0.585736:0.927987:0.585736:0.927987:0.569954:0.519047:0.569954:0.010326:0.004551:0.009827:0.008693:0.012564:0.009827:0.003024:0.010175:0.009223:0.005125:0.005020:0.009223:0.009827:0.009177:0.005125:0.004551:0.010326:0.003024:0.004188:0.008693:0.006441:0.009223:0.009827:0.004551:0.009827:0.008693:0.012564:0.010326:0.005866:0.004188:0.008693:0.009223:0.009903:0.012564:0.009827:0.008376:0.009827:0.004551:0.004188:0.008693:0.010326:0.008693:0.010311:0.009903:0.005125:0.009827:0.009223:0.005125:0.003024:0.010326:0.003024:0.004188
negative  cardiovascular effect  in  using  saxagliptin in :@0.519047:0.600122:0.927987:0.600122:0.927987:0.584339:0.519047:0.584339:0.009223:0.009827:0.010175:0.010326:0.005125:0.003024:0.008376:0.009827:0.004188:0.003432:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.007635:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.004188:0.003432:0.003024:0.009223:0.004188:0.003432:0.009192:0.005866:0.003024:0.009223:0.010175:0.004188:0.003432:0.005866:0.010326:0.007257:0.010326:0.010175:0.003024:0.003024:0.010311:0.005125:0.003024:0.009223:0.007635:0.003024:0.009223:0.004188
patients with existing heart failure. saxagliptin is, there-:@0.519047:0.614508:0.923814:0.614508:0.923814:0.598725:0.519047:0.598725:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.005503:0.012564:0.003024:0.005125:0.009223:0.005503:0.009827:0.007257:0.003024:0.005866:0.005125:0.003024:0.009223:0.010175:0.005503:0.009223:0.009827:0.010326:0.004551:0.005125:0.005503:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004188:0.005503:0.007529:0.010326:0.007257:0.010326:0.010175:0.003024:0.003024:0.010311:0.005125:0.003024:0.009223:0.005518:0.003024:0.005866:0.004188:0.005518:0.005125:0.009223:0.009827:0.004551:0.009827:0.005020
fore, contra-indicated in these patients, and there are :@0.519047:0.628893:0.928002:0.628893:0.928002:0.613111:0.519047:0.613111:0.004747:0.009903:0.004551:0.009827:0.004188:0.005458:0.009782:0.009903:0.009223:0.005125:0.004551:0.010326:0.005020:0.003024:0.009223:0.010357:0.003024:0.009782:0.010326:0.005125:0.009827:0.010357:0.005473:0.003024:0.009223:0.005473:0.005125:0.009223:0.009827:0.005866:0.009827:0.005473:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004188:0.005473:0.010326:0.009223:0.010357:0.005473:0.005125:0.009223:0.009827:0.004551:0.009827:0.005458:0.010326:0.004551:0.009827:0.004188
limitations with the use of Dpp-4 inhibitors in stage 3 renal :@0.519047:0.643279:0.928017:0.643279:0.928017:0.627496:0.519047:0.627496:0.003024:0.003024:0.014182:0.003024:0.005125:0.010326:0.005125:0.003024:0.009903:0.009223:0.005866:0.003462:0.012564:0.003024:0.005125:0.009223:0.003462:0.005125:0.009223:0.009827:0.003447:0.009192:0.005866:0.009827:0.003462:0.009903:0.004747:0.003447:0.011249:0.008950:0.008950:0.005020:0.008376:0.003462:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.003462:0.003024:0.009223:0.003462:0.005866:0.005125:0.010326:0.010175:0.009827:0.003447:0.008376:0.003462:0.004551:0.009827:0.009223:0.010326:0.003024:0.004188
dysfunction.:@0.519047:0.657665:0.607781:0.657665:0.607781:0.641882:0.519047:0.641882:0.010357:0.008104:0.005866:0.004747:0.009192:0.009223:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188
The cardiovascular outcome studies (CVOTs) in type II :@0.533335:0.672050:0.927987:0.672050:0.927987:0.656268:0.533335:0.656268:0.006441:0.009223:0.009827:0.003780:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.003780:0.009903:0.009192:0.005125:0.009782:0.009903:0.014182:0.009827:0.003765:0.005866:0.005125:0.009192:0.010357:0.003024:0.009827:0.005866:0.003780:0.005579:0.012292:0.010614:0.013138:0.006441:0.005866:0.005579:0.003795:0.003024:0.009223:0.003780:0.005125:0.008104:0.010311:0.009827:0.003780:0.003417:0.003417:0.004188
diabetes have added to our knowledge and now influ:@0.519047:0.686436:0.918795:0.686436:0.918795:0.670653:0.519047:0.670653:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.004324:0.009223:0.010326:0.008376:0.009827:0.004324:0.010326:0.010357:0.010357:0.009827:0.010357:0.004324:0.005125:0.009903:0.004324:0.009903:0.009192:0.004551:0.004309:0.007590:0.009223:0.009903:0.012564:0.003024:0.009827:0.010357:0.010175:0.009827:0.004324:0.010326:0.009223:0.010357:0.004324:0.009223:0.009903:0.012564:0.004324:0.003024:0.009223:0.003666:0.003666:0.009192
-:@0.918795:0.686436:0.923814:0.686436:0.923814:0.670653:0.918795:0.670653:0.005020
ence our choice of preferred treatment for those dia-:@0.519047:0.700821:0.923814:0.700821:0.923814:0.685039:0.519047:0.685039:0.009827:0.009223:0.009782:0.009827:0.005821:0.009903:0.009192:0.004551:0.005821:0.009782:0.009223:0.009903:0.003024:0.009782:0.009827:0.005821:0.009903:0.004747:0.005821:0.010311:0.004551:0.009827:0.004747:0.009827:0.004551:0.004551:0.009827:0.010357:0.005806:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.005806:0.004747:0.009903:0.004551:0.005821:0.005125:0.009223:0.009903:0.005866:0.009827:0.005821:0.010357:0.003024:0.010326:0.005020
betic patients with cardiovascular disease, especially :@0.519047:0.715207:0.927987:0.715207:0.927987:0.699424:0.519047:0.699424:0.010311:0.009827:0.005125:0.003024:0.009782:0.007227:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.007227:0.012564:0.003024:0.005125:0.009223:0.007227:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.007227:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.004188:0.007227:0.009827:0.005866:0.010311:0.009827:0.009782:0.003024:0.010326:0.003024:0.003024:0.008104:0.004188
ischaemic heart disease. The update of the ADA/EAsD :@0.519047:0.729593:0.927987:0.729593:0.927987:0.713810:0.519047:0.713810:0.003024:0.005866:0.009782:0.009223:0.010326:0.009827:0.014182:0.003024:0.009782:0.004808:0.009223:0.009827:0.010326:0.004551:0.005125:0.004793:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.004188:0.004808:0.006441:0.009223:0.009827:0.004793:0.009192:0.010311:0.010357:0.010326:0.005125:0.009827:0.004808:0.009903:0.004747:0.004808:0.005125:0.009223:0.009827:0.004808:0.011188:0.011249:0.011188:0.006607:0.008104:0.011188:0.007529:0.011249:0.004188
guidelines now includes specific recommendations for :@0.519047:0.743978:0.928002:0.743978:0.928002:0.728196:0.519047:0.728196:0.010175:0.009192:0.003024:0.010357:0.009827:0.003024:0.003024:0.009223:0.009827:0.005866:0.005760:0.009223:0.009903:0.012564:0.005760:0.003024:0.009223:0.009782:0.003024:0.009192:0.010357:0.009827:0.005866:0.005760:0.005866:0.010311:0.009827:0.009782:0.003024:0.003681:0.003681:0.009782:0.005760:0.004551:0.009827:0.009782:0.009903:0.014182:0.014182:0.009827:0.009223:0.010357:0.010326:0.005125:0.003024:0.009903:0.009223:0.005866:0.005745:0.004747:0.009903:0.004551:0.004188
the  SGLT2  inhibitors  (empagliflozin,  dapagliflozin)  and :@0.519047:0.758364:0.927987:0.758364:0.927987:0.742581:0.519047:0.742581:0.005125:0.009223:0.009827:0.004188:0.003674:0.007529:0.013184:0.006985:0.006441:0.008376:0.004188:0.003674:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.004188:0.003674:0.005579:0.009827:0.014182:0.010311:0.010326:0.010175:0.003024:0.003024:0.003666:0.003666:0.009903:0.006426:0.003024:0.009223:0.004188:0.004188:0.003674:0.010357:0.010326:0.010311:0.010326:0.010175:0.003024:0.003024:0.003666:0.003666:0.009903:0.006426:0.003024:0.009223:0.005579:0.004188:0.003674:0.010326:0.009223:0.010357:0.004188
the GLp-1 receptor agonist (liraglutide) to be used as :@0.519047:0.772750:0.928002:0.772750:0.928002:0.756967:0.519047:0.756967:0.005125:0.009223:0.009827:0.006395:0.013184:0.006985:0.008950:0.005020:0.008376:0.006395:0.004551:0.009827:0.009782:0.009827:0.010311:0.005125:0.009903:0.004551:0.006380:0.010326:0.010175:0.009903:0.009223:0.003024:0.005866:0.005125:0.006395:0.005579:0.003024:0.003024:0.004551:0.010326:0.010175:0.003024:0.009192:0.005125:0.003024:0.010357:0.009827:0.005579:0.006395:0.005125:0.009903:0.006395:0.010311:0.009827:0.006395:0.009192:0.005866:0.009827:0.010357:0.006395:0.010326:0.005866:0.004188
first-line therapy in patients with existing cardiovascular :@0.519047:0.787135:0.928002:0.787135:0.928002:0.771353:0.519047:0.771353:0.003681:0.003681:0.004551:0.005866:0.005125:0.005020:0.003024:0.003024:0.009223:0.009827:0.005050:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.005065:0.003024:0.009223:0.005065:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.005065:0.012564:0.003024:0.005125:0.009223:0.005050:0.009827:0.007257:0.003024:0.005866:0.005125:0.003024:0.009223:0.010175:0.005065:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.004188
disease.:@0.519047:0.801521:0.578329:0.801521:0.578329:0.785738:0.519047:0.785738:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.004188
7,8:@0.578335:0.796213:0.590480:0.796213:0.590480:0.787059:0.578335:0.787059:0.004858:0.002429:0.004858
These  agents  are  being used with increased fre-:@0.533333:0.815897:0.923812:0.815897:0.923812:0.800114:0.533333:0.800114:0.006441:0.009223:0.009827:0.005866:0.009827:0.004188:0.005715:0.010326:0.010175:0.009827:0.009223:0.005125:0.005866:0.004188:0.005715:0.010326:0.004551:0.009827:0.004188:0.005715:0.010311:0.009827:0.003024:0.009223:0.010175:0.009918:0.009192:0.005866:0.009827:0.010357:0.009918:0.012564:0.003024:0.005125:0.009223:0.009918:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.010357:0.009918:0.004747:0.004551:0.009827:0.005020
quency in the  south African context  to help prevent :@0.519045:0.830282:0.928000:0.830282:0.928000:0.814500:0.519045:0.814500:0.010311:0.009192:0.009827:0.009223:0.009782:0.008104:0.007151:0.003024:0.009223:0.007151:0.005125:0.009223:0.009827:0.004188:0.002963:0.007529:0.009903:0.009192:0.005125:0.009223:0.007151:0.011188:0.004747:0.004551:0.003024:0.009782:0.010326:0.009223:0.007151:0.009782:0.009903:0.009223:0.005125:0.009827:0.007257:0.005125:0.004188:0.002948:0.005125:0.009903:0.007151:0.009223:0.009827:0.003024:0.010311:0.007151:0.010311:0.004551:0.009827:0.008376:0.009827:0.009223:0.005125:0.004188
future cardiovascular complications and especially be-:@0.519045:0.844668:0.923812:0.844668:0.923812:0.828885:0.519045:0.828885:0.004747:0.009192:0.005125:0.009192:0.004551:0.009827:0.004203:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.004218:0.009782:0.009903:0.014182:0.010311:0.003024:0.003024:0.009782:0.010326:0.005125:0.003024:0.009903:0.009223:0.005866:0.004218:0.010326:0.009223:0.010357:0.004218:0.009827:0.005866:0.010311:0.009827:0.009782:0.003024:0.010326:0.003024:0.003024:0.008104:0.004233:0.010311:0.009827:0.005020
cause of their renal-protective effects. While the cost-:@0.519045:0.859054:0.923797:0.859054:0.923797:0.843271:0.519045:0.843271:0.009782:0.010326:0.009192:0.005866:0.009827:0.006002:0.009903:0.004747:0.005987:0.005125:0.009223:0.009827:0.003024:0.004551:0.005987:0.004551:0.009827:0.009223:0.010326:0.003024:0.005020:0.010311:0.004551:0.009903:0.005125:0.009827:0.009782:0.005125:0.003024:0.008376:0.009827:0.005987:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.005866:0.004188:0.005987:0.014514:0.009223:0.003024:0.003024:0.009827:0.006002:0.005125:0.009223:0.009827:0.005987:0.009782:0.009903:0.005866:0.005125:0.005020
effectiveness of these agents must be considered, they :@0.519045:0.873439:0.928000:0.873439:0.928000:0.857657:0.519045:0.857657:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.003024:0.008376:0.009827:0.009223:0.009827:0.005866:0.005866:0.004279:0.009903:0.004747:0.004279:0.005125:0.009223:0.009827:0.005866:0.009827:0.004279:0.010326:0.010175:0.009827:0.009223:0.005125:0.005866:0.004279:0.014182:0.009192:0.005866:0.005125:0.004279:0.010311:0.009827:0.004279:0.009782:0.009903:0.009223:0.005866:0.003024:0.010357:0.009827:0.004551:0.009827:0.010357:0.004188:0.004279:0.005125:0.009223:0.009827:0.008104:0.004188
have  additional  benefits  in  that  they  promote  weight :@0.519045:0.887825:0.928000:0.887825:0.928000:0.872042:0.519045:0.872042:0.009223:0.010326:0.008376:0.009827:0.004188:0.002495:0.010326:0.010357:0.010357:0.003024:0.005125:0.003024:0.009903:0.009223:0.010326:0.003024:0.004188:0.002495:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.005125:0.005866:0.004188:0.002480:0.003024:0.009223:0.004188:0.002495:0.005125:0.009223:0.010326:0.005125:0.004188:0.002480:0.005125:0.009223:0.009827:0.008104:0.004188:0.002480:0.010311:0.004551:0.009903:0.014182:0.009903:0.005125:0.009827:0.004188:0.002480:0.012564:0.009827:0.003024:0.010175:0.009223:0.005125:0.004188
loss, pose a low hypoglycaemia risk and offer effective :@0.519045:0.902211:0.927985:0.902211:0.927985:0.886428:0.519045:0.886428:0.003024:0.009903:0.005866:0.005866:0.004188:0.004732:0.010311:0.009903:0.005866:0.009827:0.004732:0.010326:0.004732:0.003024:0.009903:0.012564:0.004732:0.009223:0.008104:0.010311:0.009903:0.010175:0.003024:0.008104:0.009782:0.010326:0.009827:0.014182:0.003024:0.010326:0.004747:0.004551:0.003024:0.005866:0.007590:0.004732:0.010326:0.009223:0.010357:0.004732:0.009903:0.004747:0.004747:0.009827:0.004551:0.004732:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.003024:0.008376:0.009827:0.004188
glucose control. They have excellent glucose-lowering :@0.519045:0.916596:0.928000:0.916596:0.928000:0.900814:0.519045:0.900814:0.010175:0.003024:0.009192:0.009782:0.009903:0.005866:0.009827:0.005594:0.009782:0.009903:0.009223:0.005125:0.004551:0.009903:0.003024:0.004188:0.005579:0.006441:0.009223:0.009827:0.008104:0.005594:0.009223:0.010326:0.008376:0.009827:0.005594:0.009827:0.007257:0.009782:0.009827:0.003024:0.003024:0.009827:0.009223:0.005125:0.005594:0.010175:0.003024:0.009192:0.009782:0.009903:0.005866:0.009827:0.005020:0.003024:0.009903:0.012564:0.009827:0.004551:0.003024:0.009223:0.010175:0.004188
effects, particularly in those patients who start at a high :@0.519045:0.930982:0.928000:0.930982:0.928000:0.915199:0.519045:0.915199:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.005866:0.004188:0.004233:0.010311:0.010326:0.004551:0.005125:0.003024:0.009782:0.009192:0.003024:0.010326:0.004551:0.003024:0.008104:0.004248:0.003024:0.009223:0.004248:0.005125:0.009223:0.009903:0.005866:0.009827:0.004233:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004248:0.012564:0.009223:0.009903:0.004233:0.005866:0.005125:0.010326:0.004551:0.005125:0.004248:0.010326:0.005125:0.004248:0.010326:0.004248:0.009223:0.003024:0.010175:0.009223:0.004188
HbA1c level.:@0.519045:0.945367:0.611483:0.945367:0.611483:0.929585:0.519045:0.929585:0.010326:0.010311:0.011188:0.008376:0.009782:0.004188:0.003024:0.009827:0.008376:0.009827:0.003024:0.004188